Dasatinib: an inhibitor of tyrosine kinase (ITK) effective in acute transformations of CML and in Ph

被引：0
|
作者：
Rousselot, Philippe
机构：
来源：
HEMATOLOGIE | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：3
相关论文
共 50 条
  • [21] Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies
    Fauziya
    Gupta, Akash
    Nadaf, Arif
    Ahmad, Shadaan
    Hasan, Nazeer
    Imran, Mohammad
    Sahebkar, Amirhossein
    Jain, Gaurav Kumar
    Kesharwani, Prashant J.
    Ahmad, Farhan
    MEDICAL ONCOLOGY, 2023, 40 (06)
  • [22] The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice
    Kayalar, Ozgecan
    Yilmaz, Oznur
    Oztay, Fusun
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [23] Memory Impairment in Chronic phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Tanaka, Maria F.
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1610 - 1611
  • [24] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:: SCT or TKIs?
    Ruiz-Argulles, G. J.
    Tarin-Arzaga, L. C.
    Gonzalez-Carrillo, M. L.
    Gutierrez-Riveroll, K. I.
    Rangel-Malo, R.
    Gutierrez-Aguirre, C. H.
    Cantu-Rodriguez, O. G.
    Gomez-Almaguer, D.
    Giralt, S.
    BONE MARROW TRANSPLANTATION, 2008, 42 (01) : 23 - 28
  • [25] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    G J Ruiz-Argüelles
    L C Tarin-Arzaga
    M L Gonzalez-Carrillo
    K I Gutierrez-Riveroll
    R Rangel-Malo
    C H Gutiérrez-Aguirre
    O G Cantú-Rodríguez
    D Gómez-Almaguer
    S Giralt
    Bone Marrow Transplantation, 2008, 42 : 23 - 28
  • [26] Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Steinberg, Michael
    CLINICAL THERAPEUTICS, 2007, 29 (11) : 2289 - 2308
  • [27] Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells
    Okabe, Seiichi
    Moriyama, Mitsuru
    Gotoh, Akihiko
    MEDICAL ONCOLOGY, 2024, 41 (06)
  • [28] PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
    Zhang, Yingchi
    Gao, Yufeng
    Zhang, Hui
    Zhang, Jingliao
    He, Fuhong
    Hnizda, Ales
    Qian, Maoxiang
    Liu, Xiaoming
    Gocho, Yoshihiro
    Pui, Ching-Hon
    Cheng, Tao
    Wang, Qianfei
    Yang, Jun J.
    Zhu, Xiaofan
    Liu, Xin
    BLOOD, 2018, 131 (20) : 2256 - 2261
  • [29] The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era
    Cutler C.
    Antin J.H.
    Current Hematologic Malignancy Reports, 2006, 1 (3) : 160 - 167
  • [30] The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis
    Can, Guray
    Ayvaz, Suleyrnan
    Can, Hatice
    Karaboga, Ihsan
    Demirtas, Selim
    Aksit, Hasan
    Yilmaz, Bulent
    Korkmaz, Ugur
    Kurt, Mevlut
    Karaca, Turan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2016, 40 (04) : 504 - 516
12345